Eisai Forecasts Surging Leqembi Sales In Its New Fiscal Year

Launch Progresses In US, Japan And Beyond

Eisai expects growth to JPY56.5bn ($364.7m) in fiscal year 2024 from JPY4.3bn ($27.8m) in FY 2023. The company initiated a rolling BLA submission for subcutaneous Leqembi as maintenance therapy and expects approval in 2025.

Rapid growth of economic indicators. rapid growth of financial indicators of economy. economic and financial growth. — Leqembi growth will come largely from US sales, but also from Japan and other countries • Source: Shutterstock

Eisai Co., Ltd.'s most closely watched drug – the anti-amyloid antibody Leqembi (lecanemab) – contributed little revenue in the fiscal year that ended on 31 March, but the Japanese big pharma expects a big ramp up in the new year.

The firm reported JPY741.8bn ($4.79bn) in fiscal year 2023 revenue, essentially flat relative to FY 2022 revenue of JPY744.4bn ($4.81bn),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

23 Jun 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Defying Gravity: Five Drugs That Surpassed Their Sales Forecasts

20 Jun 2025

• By Edwin Elmhirst

Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

19 Jun 2025

• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.